DaVita (NYSE:DVA) Releases FY 2026 Earnings Guidance

DaVita (NYSE:DVA) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 14.100-15.200 for the period, compared to the consensus estimate of 14.130. The company issued revenue guidance of -.

DaVita Trading Up 1.9%

DVA traded up $2.90 during trading hours on Tuesday, hitting $156.98. The company’s stock had a trading volume of 1,992,106 shares, compared to its average volume of 984,548. The company has a 50-day simple moving average of $151.18 and a 200 day simple moving average of $131.51. The firm has a market capitalization of $10.49 billion, a PE ratio of 15.84, a PEG ratio of 0.53 and a beta of 0.84. DaVita has a fifty-two week low of $101.00 and a fifty-two week high of $159.42.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.33 by $0.54. The company had revenue of $3.42 billion during the quarter, compared to analyst estimates of $3.36 billion. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Research analysts expect that DaVita will post 14.16 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. UBS Group increased their target price on shares of DaVita from $186.00 to $190.00 and gave the company a “buy” rating in a research report on Wednesday, February 4th. Truist Financial set a $158.00 price target on shares of DaVita in a research note on Thursday, February 5th. TD Cowen reiterated a “hold” rating on shares of DaVita in a report on Tuesday, February 3rd. Wall Street Zen upgraded shares of DaVita from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Finally, Barclays upped their target price on DaVita from $143.00 to $158.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 3rd. One research analyst has rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $155.80.

Hedge Funds Weigh In On DaVita

Several large investors have recently made changes to their positions in the business. Invesco Ltd. grew its stake in shares of DaVita by 2.0% in the 3rd quarter. Invesco Ltd. now owns 1,679,248 shares of the company’s stock worth $223,122,000 after purchasing an additional 32,358 shares during the last quarter. Morgan Stanley lifted its stake in DaVita by 5.1% during the fourth quarter. Morgan Stanley now owns 1,477,045 shares of the company’s stock valued at $167,807,000 after purchasing an additional 71,156 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in DaVita by 0.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,089,100 shares of the company’s stock worth $123,733,000 after buying an additional 3,507 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its position in DaVita by 109.7% in the third quarter. Arrowstreet Capital Limited Partnership now owns 553,809 shares of the company’s stock worth $73,585,000 after buying an additional 289,725 shares during the last quarter. Finally, Corient Private Wealth LLC increased its holdings in shares of DaVita by 1,493.1% in the fourth quarter. Corient Private Wealth LLC now owns 358,299 shares of the company’s stock valued at $40,706,000 after buying an additional 335,809 shares in the last quarter. Institutional investors own 90.12% of the company’s stock.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.